Raising Health
The Science and Supply of GLP-1s with Chronis Manolis
Jun 11, 2024
Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, discusses the perspectives of payors and providers on anti-obesity medications, focusing on pricing and prior authorization challenges. The podcast delves into the scientific and supply aspects of GLP-1s, exploring the evolution of these drugs in healthcare, the importance of holistic support in drug prescriptions, strategies for optimizing pharmacy spend, and insights into incorporating these drugs into healthcare benefits packages.
31:30
Episode guests
AI Summary
Highlights
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Evolution in GLP-1 treatment towards more effective, tolerable formulations like once-weekly doses.
- Challenges for payors in addressing patient adherence, affordability, and coverage complexities of high-cost GLP-1 drugs.
Deep dives
Evolution of GLP-1s in Diabetes Treatment
GLP-1s have evolved significantly in diabetes treatment, shifting from older drugs to newer classes like DPP4 and SGLT2s. Social media buzz in 2023 propelled public awareness and consideration of innovative GLP-1 therapies. Market dynamics and new pipeline drugs are reshaping GLP-1 treatment guidelines and practices.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
